Miri Seiberg Ph. D. has initiated and directed hypothesis-driven research programs in the fields of skin and mucosal tissue biology, resulting in numerous innovative consumer and drug products. Her areas of expertise include technology evaluations, due diligence, IP strategy and management, and product life cycle management.
Dr. Seiberg took products for Aveeno and Neutrogena from conception and translational studies to
launch. She moved agents from the bench to clinical trials, and contributed to early drug development
and global regulatory activities. Dr. Seiberg holds more than 50 patents in the areas of skin care,
pigmentation, aging, skin cancer, hair growth, vision care, mucosal tissue health, ingestibles, and alternatives to animal testing.
Dr. Seiberg received her B.Sc. in Biology from Tel Aviv University, Israel, her M.Sc. in biochemistry from the Weizmann Institute of Science, Israel, and her Ph.D. in molecular biology from the Weizmann Institute of Science, Israel, in collaboration with Princeton University. She has worked for Bristol Myers Squibb, and currently works for the skin biology group of Johnson & Johnson. She has received numerous awards, including the Johnson Medal, the most prestigious award given for research and development at Johnson & Johnson.